Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2020

Summary of Effect of Revision on Line Items Within Statement of Operations

The effect of this revision on the line items within the statement of operations for the three months ended March 31, 2019, the six months ended June 30, 2019, the nine months ended September 30, 2019 and the year ended December 31, 2019 was as follows:

	Three Months Ended March 31, 2019
	Previously reported			Adjustments			As revised
Net loss attributable to common stockholders	$	(2,598,060	)	$	(797,637	)	$	(3,395,697	)
Net loss per share attributable to common stockholders	$	(5.22	)	$	(1.60	)	$	(6.82	)

	Six Months Ended June 30, 2019
	Previously reported			Adjustments			As revised
Net loss attributable to common stockholders	$	(5,163,387	)	$	(797,637	)	$	(5,961,024	)
Net loss per share attributable to common stockholders	$	(9.66	)	$	(1.49	)	$	(11.15	)

	Nine Months Ended September 30, 2019
	Previously reported			Adjustments			As revised
Net loss attributable to common stockholders	$	(7,951,505	)	$	(797,637	)	$	(8,749,142	)
Net loss per share attributable to common stockholders	$	(14.53	)	$	(1.46	)	$	(15.99	)

	Year Ended December 31, 2019
	Previously reported			Adjustments			As revised
Net loss attributable to common stockholders	$	(10,713,009	)	$	(797,637	)	$	(11,510,646	)
Net loss per share attributable to common stockholders	$	(19.35	)	$	(1.44	)	$	(20.79	)

Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows.

	September 30, 2020		December 31, 2019
Cash and cash equivalents	$	13,317,581	$	4,465,455
Restricted cash		75,000		75,000
Total cash, cash equivalents, and restricted cash	$	13,392,581	$	4,540,455

Summary of Accounts Payable and Other Accrued Expenses

Accounts Payable and Other Accrued Expenses:

	September 30, 2020		December 31, 2019
Trade payables	$	331,876	$	450,101
Accrued compensation and benefits		1,251,351		889,583
Accrued professional services		119,058		142,804
Warranty reserve		154,722		81,981
Other		265,133		174,021
	$	2,122,140	$	1,738,490

Summary of Revenue by Major Source

The following table presents revenue by major source:

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2020		2019		2020		2019
Clinical/Medical providers	$	612,207	$	405,914	$	1,433,276	$	1,837,667
Direct to patient		1,314,453		200,705		2,360,119		479,367
Total revenue from contracts with customer	$	1,926,660	$	606,619	$	3,793,395	$	2,317,034

Summary of Potential Common Shares Issuable

Potential common shares issuable consist of the following at:

	September 30,
	2020		2019
Stock options		19,387		22,293
Restricted stock units		271,984		12,844
Restricted stock		122		342
Stock warrants		2,460,069		181,176
Total		2,751,562		216,655